Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line

International Journal of Cancer

Volumn 66, Issue 4, 1996, Pages 506-514

  Abbaszadegan, Mohammad R ^a,b   Foley, Nils E ^a,b   Gleason Guzman, Mary C ^a,b   Dalton, William S ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZIDOPINE; CHEMOSENSITIZING AGENT; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MELPHALAN; METHOTREXATE; MITOXANTRONE; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; PRIORITY JOURNAL;

CALCIUM CHANNEL BLOCKERS; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION; HUMANS; MULTIPLE MYELOMA; P-GLYCOPROTEIN; RNA, MESSENGER; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0029903047     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960516)66:4<506::AID-IJC14>3.0.CO;2-5     Document Type: Article

References (41)

1. ABBASZADEGAN, M.R., FUTSCHER, B.W., KLIMECKI, W.T., LIST, A. and DALTON, W.S., Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res., 54, 4676-4679 (1994).
2. ALLEY, M.C., SCUDIERO, D.A., MONKS, A., HURSEY, M.L., CZERWINSKI, M.J., FINE, D.L.A., MAYO, J.G., SHOEMAKER, R.H. and BOYD, M.R., Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 48, 589-601 (1988).
3. BECK, W.T., Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance. J. nat. Cancer Inst., 81, 1683-1685 (1989).
4. BECK, W.T., Modulators of P-glycoprotein-associated multidrug resistance. In: R.F. Ozols (ed.), Molecular and clinical advances in anticancer drug resistance, pp. 151-170, Kluwer, Boston (1991).
5. BELLAMY, W.T., DALTON, W.S., KAILEY, J.M., GLEASON, M.C., MC-CLOSKEY, T.M., DORR, R.T. and ALBERTS, D.S., Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res., 48, 6365-6370 (1988).
6. CHOI, K.H., CHEN, C.J., KRIEGLER, M. and RONINSON, I.B., An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell, 53, 519-529 (1988).
7. COLE, S.P.C., BHARDWAJ, G., GERLACH, J.H., MACKIE, J.E., GRANT, C.E., ALMQUIST, K.C., STEWART, A.J., KURZ, E.U., DUNCAN, A.M.V. and DEELEY, R.G., Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258, 1650-1654 (1992).
8. DALTON, W.S. Overcoming the multidrug-resistant phenotype. In: V. DeVita, Jr., S. Hellman and S.A. Rosenberg (eds.), Cancer: principles and practice of oncology, pp. 2655-2666, J.B. Lippincott, Philadelphia (1993).
9. DALTON, W.S., DURIE, B.G.M., ALBERTS, D.S., GERLACH, J.H. and CRESS, A.E., Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res., 46, 5125-5130 (1986).
10. DALTON, W.S., GROGAN, T.M., MELTZER, P.S., SCHEPER, R.J., DURIE, B.G.M., TAYLOR, C.W., MILLER, T.P. and SALMON, S.E., Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. clin. Oncol., 7, 415-424 (1989).
11. DALTON, W.S. and SIKIC, B.I., The multidrug-resistance gene (MDR1) represents a potential target for reversing drug resistance in human malignancies. (Controversies in science: multidrug resistance). J. NIH Res., 6, 54-61 (1994).
12. DANKS, M.K., SCHMIDT, C.A., CIRTAIN, M.C., SUTTLE, D.P. and BECK, W.T., Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry, 27, 8861-8869 (1988).
13. DEELEY, R.G., GRANT, C.E., ALMQUIST, K.C., HIPFNER, D.R., VALDIMARSSON, G., LOE, D.W., GALLEN, D.F., KUSS, B. and COLE, S.P.C., Multidrug resistance mediated by the 190 kD MRP, a novel member of the ATP-binding cassette transporter superfamily. Proc. amer. Assoc. Cancer Res., 35, 698-699 (1994).
14. DEVINE, S.E., LING, V. and MELERA, P. W., Amino acid substitutions in the sixth transmembrane domain of P-glycoprotein alter multidrug resistance. Proc. not. Acad. Sci. (Wash.), 89, 4564-4568 (1992).
15. FERNANDES, D.J., CATAPANO, C.V. and TOWNSEND, A.J., Topoisomerase-related mechanisms of drug resistance. In: B.A. Teicher (ed.), Drug resistance in oncology, pp. 479-498, M. Decker, New York (1993).
16. FUTSCHER, B.W., ABBASZADEGAN, M.R., DOMANN, F. and DALTON, W.S., Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem. Pharmacol., 47, 1601-1606 (1994).
17. FUTSCHER, B.W., BLAKE, L.L., GERLACH, J.H., GROGAN, T.M. and DALTON, W.S., Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens. Anal. Biochem., 213, 414-421 (1993).
18. GRANT, C.E., VALDIMARSSON, G., HIPFNER, D.R., ALMQUIST, K.C., COLE, S.P.C. and DEELEY, R.G., Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res., 54, 357-361 (1994).
19. GROS, P., DHIR, R., CROOP, J. and TALBOT, F., A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. Proc. nat. Acad. Sci. (Wash.), 88, 7289-7293 (1991).
20. HAMADA, H., MIURA, K., ARIYOSHI, K., HEIKEY, SATA, S., KAMEYAMA, K., KUROSAWA, Y. and TSURUO, T., Mouse-human chimeric antibody against the multidrug transporter P-glycoprotein. Cancer Res., 50, 3167-3171 (1990).
21. KAJIJI, S., DRESLIN, J.A., GRIZZUTI, K. and GROS, P., Structurally distinct MDR modulators show specific patterns of reversal against P-glycoproteins bearing unique mutations at serine939/941. Biochemistry, 33, 5041-5048 (1994).
22. LIST, A.F., SPIER, C., GREER, J., WOLFF, S., HUTTER, J., DORR, R., SALMON, S., FUTSCHER, B., BAIER, M. and DALTON, W., Phase I/I1 trial of cyclosporine as a chemotherapy-resisance modifier in acute leukemia [see comments]. J. clin. Oncol., 11, 1652-1660 (1993).
23. LIU, L.F., ROWE, T.C., YANG, L., TEWEY, K.M. and CHEN, G.L., Cleavage of DNA by mammalian DNA topoisomerase II. J. biol. Chem., 258, 15365-15370 (1983).
24. MARIE, J.P., BASTIE, J.N., COLOMA, F., FAUSSAT SUBERVILLE, A.M., DELMER, A., RIO, B., DELMAS-MARSALET, B., LEROUX, G., CASASSUS, P., BAUMELOU, E., CATALIN, J. and ZITTOUN, R., Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). Leukemia, 7, 821-824 (1993).
25. MILLER, T.P., GROGAN, T.M., DALTON, W.S., SPIER, C.M., SCHEPER, R.J. and SALMON, S.E., P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. clin. Oncol., 9, 17-24 (1991).
26. NELSON, E.M., TEWEY, K.M. and LIU, L.F., Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide. Proc. nat. Acad. Sci. (Wash.), 81, 1361-1365 (1984).
27. RIORDAN, J.R. and LING, V., Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J. biol. Chem., 254, 12701-12705 (1979).
28. SAFA, A.R., Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc. nat. Acad. Sci. (Wash.), 85, 7187-7191 (1988).
29. SAFA, A.R., GLOVER, C.J., MEYERS, M.B., BIEDLER, J.L. and FELSTED, R.L., Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells. J. biol. Chem., 261, 6137-6140 (1986).
30. SAFA, A.R., GLOVER, C.J., SEWELL, J.L., MEYERS, M.B., BIEDLER, J.L. and FELSTED, R.L., Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J. biol. Chem., 262, 7884-7888 (1987).
31. SAFA, A.R., STERN, R.K., CHOI, K., AGRESTI, M., TAMAI, I., MEHTA, N.D. and RONINSON, I.B., Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185 → Val-185 substitution in P-glycoprotein. Proc. nat. Acad. Sci. (Wash.), 87, 7225-7229 (1990).
32. SALMON, S.E., DALTON, W.S., GROGAN, T.M., PLEZIA, P., LEHNERT, M., ROE, D.J. and MILLER, T.P., Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood, 78, 44-50 (1991).
33. SIKIC, B.I., Modulation of multidrug resistance: at the threshold [editorial; comment]. J. clin. Oncol., 11, 1629-1635 (1993).
34. SONNEVELD, P., DURIE, B.G.M., LOKHORST, H.M., MARIE, J.P., SOLBU, G., SUCIU, S., ZITTOUN, R., LOWENBERG, B. and NOOTER, K., Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON [see comments]. Lancet, 340, 255-259 (1992).
35. TSURUO, T., IIDA, H., TSUKAGOSHI, S. and SAKURAI, Y., Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res., 41, 1967-1972 (1981).
36. TSURUO, T., IIDA, H., TSUKAGOSHI, S. and SAKURAI, Y., Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res., 42, 4730-4733 (1982).
37. TSURUO, T., KAWABATA, H., IIDA, H., KITATANI, Y., TSUKAGOSHI, S. and SAKURAI, Y., Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns. Cancer Chemother. Pharmacol., 15, 16-19 (1985).
38. TWENTYMAN, P.R., FOX, N.E. and WHITE, D.J.G., Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistance human lung cancer cell line. Brit. J. Cancer, 56, 55-57 (1987).
39. WELLS, D., HOFFMAN, D. and KEDES, L., Unusual structure, evolutionary conservation of non-coding sequences and numerous pseudogenes characterize the human H3.3 histone multigene family. Nucleic Acids Res., 15, 2871-2889 (1987).
40. WELLS, D. and KEDES, L., Structure of a human histone cDNA: evidence that basally expressed histone genes have intervening sequences and encode polyadenylylated mRNAs. Proc. nat. Acad. Sci (Wash.), 82, 2834-2838 (1985).
41. WOLVERTON, J.S., DANKS, M.K., SCHMIDT, C.A. and BECK, W.T., Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells. Cancer Res., 49, 2422-2426 (1989).